NK - NantKwest, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.54
-0.67 (-10.79%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.21
Open6.50
Bid5.61 x 1300
Ask5.70 x 2900
Day's Range5.53 - 6.63
52 Week Range0.95 - 9.90
Volume1,675,969
Avg. Volume1,351,598
Market Cap545.74M
Beta (5Y Monthly)3.05
PE Ratio (TTM)N/A
EPS (TTM)-0.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
  • Hedge Funds Cashing Out Of Nantkwest Inc (NK)
    Insider Monkey

    Hedge Funds Cashing Out Of Nantkwest Inc (NK)

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates
    Benzinga

    NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates

    Nantkwest Inc (NASDAQ: NK) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options.Vaccine Program Part Of 'Operation Warp Speed'El Segundo, California-based NantKwest said its affiliate ImmunityBio has been selected to participate in Operation Warp Speed, a national program aimed at providing substantial quantities of safe, effective vaccine for Americans by January 2021.NanKwest said it will focus on developing, testing and largescale manufacturing of ImmunityBio's COVID-19 human adenovirus vaccine candidate, codenamed hAd5. The company said it's the first vaccine designed to deliver both Spike and Nucleocapsid DNA, offering scope for long-lasting immunity."ImmunityBio is honored to have been selected as one of the 14 companies for Operation Warp Speed and is committed to moving our vaccine candidate through the process to prevent people from contracting this deadly virus," said Patrick Soon-Shiong, CEO of ImmunityBio and NantKwest.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.COVID Therapeutics NantKwest will evaluate ImmunityBio's N-803, an interleukin 15 as well its own haNK, off-the-shelf natural killer cells, to treat mild-to-moderate COVID-19 symptoms. Phase 1 trials for N-803 is set to begin in Los Angeles in June."Based on initial data, we believe our IL-15 superagonist N-803 could prevent patients from reaching the most advanced stages of disease, including pneumonia and acute respiratory distress syndrome," Soon-Shiong said.Meanwhile, the company has filed a pre-IND application to the FDA for haNK.For severe and critically ill COVID-19 patients on ventilator support, NantKwest's bone marrow-derived mesenchymal stem cells are being evaluated. The company initiated a Phase 1b study on May 18 to evaluate the safety and efficacy of BM-Allo.MSC versus current supporting care.The companies also said the FDA has authorized the use of ImmunityBio's IL-15 to treat patients prior to the onset of severe disease by potentially activating natural killer cells to mitigate viral replication.Alliance Firmed Up NantKwest and ImmunityBio have agreed to jointly develop haNK, mesenchymal stem cells, adenovirus constructs, and N-803 for the prevention and treatment of SAR-CoV-2 viral infections and associated conditions, including COVID-19.The agreement calls for both parties sharing equally in all costs relating to developing, manufacturing and marketing of the product candidates globally, with net profits from the collaboration products to be shared 60%/40% in favor of the party contributing the product.At last check, NantKwest shares were surging by 20% to $6.53.See more from Benzinga * The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO * NantKwest In 'Active Discussions' With FDA On COVID-19 Vaccine, Therapeutic Development(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
    Business Wire

    ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine

    NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio’s COVID-19 human adenovirus vaccine (hAd5) candidate. This is the first vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA, offering the potential for patients to develop long-lasting immunity to the virus.

  • NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
    Business Wire

    NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference

    NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET.

  • Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths
    Business Wire

    Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths

    Be The Match BioTherapies is providing donor material for a NantKwest Phase 1b trial to address one of the primary causes of COVID-19 deaths.

  • NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
    Business Wire

    NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients

    NantKwest, Inc. (NASDAQ: NK) today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC, an allogeneic mesenchymal stem cell (MSC) product derived from human bone marrow. NantKwest has entered into an agreement with the National Marrow Donor Program (Be the Match) to provide donor material and has developed automated proprietary methods to expand and generate multiple dose forms utilizing a modular, closed system (GMP-in-a-box) from NantKwest affiliate ImmunityBio, Inc., to expand BM-Allo.MSCs, enabling the scalable manufacture and immediate distribution of cryopreserved BM-Allo.MSC product.

  • The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
    Benzinga

    The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) * Allogene Therapeutics Inc (NASDAQ: ALLO)(reacted to ASCO abstract) * Altimmune Inc (NASDAQ: ALT)(announced first-quarter results and update to its COVID-19 vaccine program) * BioXcel Therapeutics Inc (NASDAQ: BTAI)( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) * Co-Diagnostics Inc (NASDAQ: CODX) * Myokardia Inc (NASDAQ: MYOK) * Repligen Corporation (NASDAQ: RGEN) * Translate Bio Inc (NASDAQ: TBIO) * VBI Vaccines Inc (NASDAQ: VBIV)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) * Genfit SA (NASDAQ: GNFT) * Lyra Therapeutics Inc (NASDAQ: LYRA) (IPOed May 1) * RA Medical Systems Inc (NYSE: RMED)(reacted to first-quarter results) * Recro Pharma Inc (NASDAQ: REPH) * Sensus Healthcare Inc (NASDAQ: SRTS) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONNStocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ:NK) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.The company noted that out of the four patients treated with PD-L1 t-haNK and N-803 under single patient INDs, two were on treatment for the evaluable period. Of these two patients, one reported ongoing, durable, complete response six months after treatment, and one observed response of stable disease. It expects to begin the Phase 2 study in June."Our results from expanded access use of PD-L1 t-haNK in combination with N-803 offer proof-of-concept that, together with these agents, the immune system may play a role to activate robust and durable responses in metastatic cancer patients who have failed all standard-of-care therapies, said Patrick Soon-Shiong, CEO of NantKwest and ImmunityBio.NantKwest stock fell 8.54% to $4.71 in after-hours trading.Phio Presents Encouraging Data For Gene Silencing Platform Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced data analyzing the applicability of the INTASYL platform as a gene silencing technology that offers an alternative or complementary approach to gene editing technologies, such as CRISPR/Cas9, in the treatment of solid tumors.The data presented as a poster at the American Society of Gene and Cell Therapy 23rd Virtual Annual Meeting showed that INTASYL compared favorably to other technologies for improving cells used in adoptive cell therapy for the treatment of solid tumors, especially in cases where permanent gene modification is not required or is undesirable.The stock rose 5.14% to $2.25 in after-hours trading.Earnings Sellas Life Sciences Group Inc (NASDAQ: SLS) reported a first-quarter net loss of 66 cents per share compared to a loss of $11.12 per share last year. Analysts estimated a wider loss of 74 cents per share. Cash and cash equivalents totaled about $6.7 million at the end of March 31, 2020, compared to $2.6 million as of March 31, 2019The stock rallied 13.24% to $3.25 in after-hours trading.Applied DNA Sciences Inc's (NASDAQ: APDN) fiscal year second-quarter revenues fell 29% year-over-year to $552,000. The net loss narrowed from $1.12 per share to 79 cents per share. Analysts, on average, estimated a loss of 77 cents per share on revenues of $950,000.View more earnings on IBBIn after-hours trading, the stock was down 11.77% to $13.42.TFF Pharmaceuticals Inc (NASDAQ: TFFP) reported a first-quarter loss of 20 cents per share compared to a loss of 55 cents per share a year ago. Analysts estimated a loss of 24 cents per share. The stock jumped 17.02% to $5.50 in after-hours trading.Co-Diagnostics reported a strong increase in its first-quarter revenues to $1.55 million from $3,400 a year ago. The loss per share narrowed from 9 cents to 5 cents, in line with estimate.Offering a mid-quarter update for the second quarter, the company said it has manufactured more than 6 million COVID-19 tests to date and has ordered for components for more than 20 million additional tests. The company also said its test kit showed 100% specificity and 100% sensitivity in several independent evaluations.The stock retreated 15.95% to $18.60 in after-hours trading.Offerings TG Therapeutics Inc common stock (NASDAQ: TGTX) priced its upsized underwritten public offering of 8.5 million shares at $18 per share for raising gross proceeds of $153 million. All the shares are being offered by the company. The company expects the offering to close May 19.The stock slipped 2.26% to $19.48 in after-hours trading.Boston Scientific Corporation (NYSE: BSX) priced its public offering of $1.7 billion aggregate principal amount of its senior notes.The public offering consists of $500 million in aggregate principal amount of 1.90% notes due 2025 and $1.2 billion in aggregate principal amount of 2.65% notes due 2030. The company intends to use the net proceeds to repay its debt.Oyster Point Pharma Inc (NASDAQ: OYST) priced its underwritten public offering of 3.75 million shares at $28 per share. All of the shares are being offered by the company. The offering, which is expected to close May 19, is likely to generate gross proceeds of $105 million for the company.The stock was slipping 6.31% to $30.01 in premarket trading Friday.On The Radar PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS) awaits FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.Clinical Readouts Pfizer Inc. (NYSE: PFE) will present at the ASGCT meeting, Phase 1b data for PF-06939926 in Duchenne muscular dystrophy at 10 am ET.Earnings Digirad Corporation (NASDAQ: DRAD) (before the market open) * Zyla Life Sciences (OTC: ZCOR) (before the market open) * PLx Pharma Inc (NASDAQ: PLXP) (before the market open) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP) (before the market open) * Bio-Path Holdings Inc (NASDAQ: BPTH) (before the market open)IPO Late clinical-stage oncology-focused Swiss biotech ADC THERAPEUTICS priced its upsized initial public offering of 12,245,631 shares of its common shares at $19.00 per share, above the estimated price range of $16-18. The company expects the offering to generate gross proceeds of $232.7 million. The shares are to be listed on the NYSE under the ticker symbol "ADCT."See more from Benzinga * The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger * The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
    Business Wire

    NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer

    NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of their combination immunotherapy: NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.

  • NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
    Business Wire

    NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference

    NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET.

  • NantKwest aims to start clinical trials for COVID-19 vaccine by June
    American City Business Journals

    NantKwest aims to start clinical trials for COVID-19 vaccine by June

    Dr. Patrick Soon-Shiong’s NantKwest Inc. and ImmunityBio Inc. are developing potential vaccines and therapeutics to combat COVID-19.

  • NantKwest In 'Active Discussions' With FDA On COVID-19 Vaccine, Therapeutic Development
    Benzinga

    NantKwest In 'Active Discussions' With FDA On COVID-19 Vaccine, Therapeutic Development

    Shares of small-cap immunotherapy company Nantkwest Inc (NASDAQ: NK), a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, were adding to Monday's gains in Tuesday's session. NantKwest and its affiliate ImmunityBio are in "active discussions" with the FDA about developing therapies and vaccines to combat the COVID-19 pandemic, the companies said in a Tuesday press release. ImmunityBio will contribute its expertise in vaccine development and NK cell activation, while NantKwest will pitch in with its off-the-shelf cell-based therapies.ImmunityBio and NantKwest said they have developed immunomodulator regimens for COVID-19 based on the biological stage of the patient's infection -- mild, moderate and severe or critically ill. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.NantKwest, ImmunityBio's COVID-19 Strategy With the mild-to-moderate stage of infection, the companies said NK and T cell stimulation should work and are proposing clinical trials of N-803 alone and a second trial of haNK alone, or haNK combined with convalescent plasma.The companies said IND applications for the trials are pending before the FDA.For patients requiring ventilator support, the companies are exploring the use of bone marrow-derived allogenic mesenchymal stem cells to mitigate the cytopathic storm.The companies also said they are developing a vaccine platform for both initial immunizations and subsequent booster injections."We're in a race against time, but I am confident that, as a result of the incredible hard work the NantKwest, ImmunityBio, and the global scientific communities are undertaking, we will find effective therapeutics and vaccines against this coronavirus," Patrick Soon-Shiong, the chairman and CEO of NantKwest and ImmunityBio, said in a statement. NantKwest shares were rising by 10.83% to $3.48 at the time of publication Tuesday.Related Links:The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates Gilead Analysts Break Down Remdesivir Data Readout From Compassionate UseSee more from Benzinga * GlaxoSmithKline, Sanofi Collaborate On COVID-19 Vaccine Development: What You Should Know * The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership * Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
    Business Wire

    NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter

    NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., clinical-stage immunotherapy companies within the NantWorks family of companies, today announced they are in active discussions with the U.S. Food and Drug Administration (FDA) for vaccines and therapeutics to combat COVID-19.

  • NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
    Business Wire

    NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells

    NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced dosing of the first patient in a Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC) in patients who are refractory to immune checkpoint inhibitors. The trial will evaluate the Company’s first-in-class, off-the-shelf CD16-targeted natural killer (haNK) cells in combination with ImmunityBio’s IL-15 superagonist N-803 and Avelumab.

  • Options Traders Expect Huge Moves in NantKwest (NK) Stock
    Zacks

    Options Traders Expect Huge Moves in NantKwest (NK) Stock

    Investors need to pay close attention to NantKwest (NK) stock based on the movements in the options market lately.

  • Investors Who Bought NantKwest (NASDAQ:NK) Shares A Year Ago Are Now Up 199%
    Simply Wall St.

    Investors Who Bought NantKwest (NASDAQ:NK) Shares A Year Ago Are Now Up 199%

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...

  • Here is What Hedge Funds Think About Nantkwest Inc (NK)
    Insider Monkey

    Here is What Hedge Funds Think About Nantkwest Inc (NK)

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • Benzinga

    The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...

  • What Kind Of Shareholder Owns Most NantKwest, Inc. (NASDAQ:NK) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most NantKwest, Inc. (NASDAQ:NK) Stock?

    If you want to know who really controls NantKwest, Inc. (NASDAQ:NK), then you'll have to look at the makeup of its...

  • Does NantKwest, Inc.'s (NASDAQ:NK) CEO Pay Reflect Performance?
    Simply Wall St.

    Does NantKwest, Inc.'s (NASDAQ:NK) CEO Pay Reflect Performance?

    In 2015 Patrick Soon-Shiong was appointed CEO of NantKwest, Inc. (NASDAQ:NK). This report will, first, examine the CEO...

  • Who Has Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?
    Simply Wall St.

    Who Has Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%?
    Simply Wall St.

    Did Changing Sentiment Drive NantKwest's (NASDAQ:NK) Share Price Down A Painful 82%?

    NantKwest, Inc. (NASDAQ:NK) shareholders should be happy to see the share price up 11% in the last month. But only the...